Genentech to expand Hillsboro facility in Oregon, US

Published: 30-Mar-2015
Manufacturing Pharmaceutical

Will bring up to 100 new jobs to the state


Genentech, a Roche Group company headquartered in South San Francisco, CA, US, plans to invest more than US$125m to expand its fill/finish facility in Hillsboro, Oregon, US.

Larry Sanders, General Manager and Vice President, Hillsboro Technical Operations, said the investment in the biotechnology company's sterile production operations will result in the addition of up to 100 skilled manufacturing jobs in the greater Portland area over the next five years, potentially bringing the total number of Genentech jobs in Oregon to more than 500.

Genentech started operations in Hillsboro in April 2010. As well as the fill/finish facility, the site also includes a warehousing and distribution centre. Increasing manufacturing capacity will help the company meet growing demand for its products.

  • Companies:
  • Genentech
See more

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Read more
Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
Manufacturing

Ensuring robust lyophilisation scale-up

SP Scientific announces the on-demand availability of a popular webinar by Jake Luoma of Genentech that discusses how controlled nucleation has emerged as a technology that promises improvements in lyophilisation throughput and consistency
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Manufacturing

Genentech to expand California biologics manufacturing facilities

Investment of $285m will create more than 250 new jobs
Regulatory

A lucrative niche in orphan diseases?

The number of potential blockbuster drugs is in decline so many Big Pharma companies are looking to rare diseases to fill their pipelines because low sales volumes can be balanced out by premium prices.
Subscribe now